Portfoliotracker

Curatis Holding AG

CURN.SW · SWISS · Healthcare Drug Manufacturers - Specialty & Generic 16/100 E

16,00 CHF
▲ +0,95 (+6,31 %)
Trading delayed by 15 min
Price as of 17. 11. 13:31, fetched 17. 11. 14:45
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score16 / 100 Market cap79,8 mil. CHF P/E– Forward P/E31,4 P/S5,9 P/B1,6 EV/EBITDA– Dividend yield– FCF yield-3,46 % EPS-0,13 CHF Net margin-4,9 % Return on equity-1,4 % Beta-0,64 Debt / equity–
52-week range 11,05 to 27,90
3-month average volume0,0 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collagen sponge, benign prostatic hyperplasia, immunomodulator, epilepsy and essential tremor, thyreostatic, hereditary tyrosinemia type 1, nootropic, tranquilizer, helicobacter pylori test, phosphate binder, special nutrition for dialysis patients, dermato corticosteroid, lead and mercury poisoning, corticostimulin, anti-fog agent, chorea associated with huntington's disease, and antiepileptic. The company also develops C-PTBE-01, which is in Phase IIb clinical trial for the treatment of peritumoral brain edema; C-AM-01 that is in Phase IIa clinical trial for the prevention of severe migraine with aura; C-MOH-01, which is in Phase IIa clinical trial for the treatment and prevention of medication overuse headache; and C-FI-01 that is in phase I clinical trial for the treatment of fibrotic or inflammatory orphan or ultra-orphan diseases. The company was founded in 2002 and is based in Liestal, Switzerland.

Employees
9
Country
Switzerland
Data since
16. 4. 1999

Explore further

Similar companies KURN.SWSANN.SWNWRN.SWSFZN.SWBSLN.SW

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account